Dulaglutide vs Tirzepatide
Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Dulaglutide
1.5–1.5 mg
Tirzepatide
5–10 mg
Frequency
Dulaglutide
Once weekly
Tirzepatide
Once weekly
Administration
Dulaglutide
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle length
Dulaglutide
Ongoing/indefinite
Tirzepatide
Ongoing/indefinite
Onset speed
Dulaglutide
Gradual (3-4 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence level
Dulaglutide
Strong human trials (Phase 3 or FDA approved)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Metabolic
Weight Management
Healing & Recovery
Weight Loss
Appetite Control
Blood Sugar Control
Compound specifications
Dulaglutide
Molecular formula
C2646H4044N704O836S18 (complete fusion protein homodimer)
Molecular weight
~63 kDa (~59,670 Da per chain)
Half-life
~5 days (terminal elimination); Tmax ~48 hours; steady state in 2–4 weeks; accumulation ratio 1.56 at 1.5 mg
Bioavailability
47–65% after subcutaneous injection (dose-dependent); apparent clearance 0.142 L/h
CAS number
923950-08-7
Tirzepatide
Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2
Dosing compared
Dulaglutide
Subcutaneous
4 weeks before increasing
0.75 mg
Once weekly · 4 weeks before increasing
FDA-approved starting dose for type 2 diabetes. Injected under the skin of the abdomen, thigh, or upper arm on the same day each week [4].
Ongoing
1.5 mg
Once weekly · Ongoing
Common maintenance dose. The dose can be raised from 0.75 mg after at least 4 weeks if more blood-sugar control is needed [1][4].
Ongoing
3.0–4.5 mg
Once weekly · Ongoing
FDA-approved higher doses. In the AWARD-11 trial, stepping up to 3.0 mg then 4.5 mg gave added blood-sugar and weight benefits; 4.5 mg is the maximum dose [1].
Tirzepatide
Subcutaneous injection
First 4 weeks
2.5 mg
Once weekly · First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
Increase by 2.5 mg after at least 4 weeks at each dose
5-10 mg
Once weekly · Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Ongoing maintenance
12.5-15 mg
Once weekly · Ongoing maintenance
15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Best suited for
Dulaglutide
Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Side effects
Dulaglutide
Common
- Nausea
- Diarrhea and abdominal pain
- Vomiting
- Decreased appetite
Uncommon
- Injection site reactions and fatigue
Serious
- Acute pancreatitis
- Gallbladder disease
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
Dulaglutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models. This risk is contraindicated in patients with personal or family history of MTC [6] or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common. Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor data [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
- Known serious hypersensitivity to dulaglutide or any excipient [6]
- Type 1 diabetes mellitus or diabetic ketoacidosis (not indicated) [6]
Tirzepatide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Which is right for you?
Choose Dulaglutide if...
- Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
- Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
- Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
- Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement